Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting.
10.1007/s11684-025-1140-8
- Author:
Haohua ZHU
1
;
Song HUANG
2
;
Xingsheng HU
3
,
4
Author Information
1. Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
2. Value & Implementation, Global Medical & Scientific Affairs, MSD China, Shanghai, 200233, China.
3. Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. huxingsheng66@
4. com.
- Publication Type:Review
- Keywords:
China;
antiemetics;
neurokinin-1 receptor antagonists;
vomiting
- MeSH:
Humans;
Vomiting/prevention & control*;
Neurokinin-1 Receptor Antagonists/therapeutic use*;
Nausea/prevention & control*;
Antiemetics/therapeutic use*;
Antineoplastic Agents/adverse effects*;
Aprepitant/therapeutic use*;
Morpholines/therapeutic use*
- From:
Frontiers of Medicine
2025;19(4):600-611
- CountryChina
- Language:English
-
Abstract:
Chemotherapy-induced nausea and vomiting (CINV) is common in patients receiving moderately or highly emetogenic chemotherapy and is caused by the activation of peripheral and central nervous system pathways, with the neurokinin-1 receptor playing a central role in delayed CINV. Neurokinin-1 receptor antagonists (NK1RAs) in combination with other antiemetic agents are recommended in international and Chinese guidelines for the prevention of acute and delayed CINV. Therefore, a summary of current data for NK1RAs would be of great clinical utility. This article summarizes the available clinical and real-world data on the use of NK1RAs in CINV prophylaxis, with a focus on evidence from China, where three NK1RAs, aprepitant, fosaprepitant and netupitant, are currently approved. NK1RAs have demonstrated efficacy and favorable safety in the prevention of acute and delayed CINV. Further research is required to determine the optimal use of these drugs and to identify strategies for CINV management in specific patient populations.
